Загрузка...
Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials
BACKGROUND: Renal impairment is not a consistently cited risk factor for recurrent Clostridioides difficile infection (rCDI). We examined the association between renal impairment and rCDI and the effect of bezlotoxumab, an anti–toxin B monoclonal antibody, in reducing rCDI in participants with renal...
Сохранить в:
| Опубликовано в: : | Open Forum Infect Dis |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7357450/ https://ncbi.nlm.nih.gov/pubmed/32685606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa248 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|